Assessment of joint health in patients receiving prophylaxis for haemophilia A: a cross-sectional survey in five European countries
In this multinational real-world study, nearly two-thirds of adults with moderate/severe haemophilia A without inhibitors experienced HAJs despite prophylaxis. Individuals with HAJs had higher rates of pain and pain medication use, and lower HRQoL compared with those without HAJs. These data indicate that HAJs represent a clinically relevant burden and early identification/monitoring and management of affected joints should be an important consideration to help prevent long-term joint morbidity.
Authors
- Zalmaï Hakimi (ORCID: https://orcid.org/0000-0001-5835-8599)
- Keisha Golden (ORCID: https://orcid.org/0000-0002-8340-6430)
- N. A. Ball (ORCID: https://orcid.org/0000-0002-4150-1106)
- Nana Kragh (ORCID: https://orcid.org/0000-0002-9222-4479)
- Hortensia De la Corte‐Rodríguez (ORCID: https://orcid.org/0000-0002-9179-201X)
- Stevie Olsen (ORCID: https://orcid.org/0000-0002-8911-0155)
- Linda Bystrická (ORCID: https://orcid.org/0000-0002-9787-7866)
Institutions
- Hospital Universitario La Paz (ES)
- Adelphi Group (United Kingdom) (GB)
- Swedish Orphan Biovitrum (Sweden) (SE)
Publication Details
- Journal
- BMJ Open
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1136/bmjopen-2023-082204
- Citations
- 4
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Sanofi
- Swedish Orphan Biovitrum